Cosmos Health Inc.

Cosmos Health Inc. provided an update on its U.S. business, expecting fourth-quarter 2026 revenue of approximately $15 million and gross profit of $10.5 million. The company reported a significant increase in active U.S. subscriptions, reaching 8,940 as of October 19, 2026, a 42% jump in five days. The CEO's letter to shareholders also highlighted strong preliminary nine-month 2026 revenue of $54.3 million and reaffirmed a full-year revenue outlook exceeding $90 million.

Cosmos Health Inc. announced the active development of a new digital subscription platform for its proprietary consumer health products. This platform will cater to both individual consumers (B2C) and corporate clients (B2B), offering personalized packages and multiple entry points including nutritionist consultations and AI assistance. The initiative aims to build a scalable, technology-enabled, recurring-revenue business, leveraging the success of its NOOR Collagen subscription model which boasts a repeat purchase rate above 60%.

Cosmos Health Inc. announced an expansion of its partnership with Pharma Cell for the distribution of its Sky Premium Life brand in Albania. The company anticipates that orders under this expanded relationship will exceed 54,000 units on an annualized basis, with average monthly orders already surpassing 4,500 units. This expansion builds on the successful partnership launched in April 2025 and reflects the strong reception of Sky Premium Life products, which are recommended by doctors and healthcare professionals across Albania.

Cosmos Health Inc. announced it has repurchased an additional 274,000 shares of its common stock at an average price of approximately $0.2554 per share. This brings the total shares repurchased under its program to 5,112,000 for approximately $1.11 million. The company intends to continue open market repurchases under the program, which expires on December 31, 2026, as CEO Greg Siokas believes the shares remain undervalued.

Cosmos Health Inc. held its 2026 Annual Meeting of Stockholders on July 15, 2026, where all proposals were approved. Stockholders elected six directors to the Board and authorized the issuance and designation of 100,000 shares of Series B Preferred Stock. Additionally, the 2026 Equity Omnibus Plan was approved, and the appointment of the independent registered public accounting firm was ratified. Approximately 47% of the company's outstanding shares were represented at the meeting.

Cosmos Health Inc. announced it has repurchased an additional 250,000 shares of its common stock at an average price of approximately $0.2782 per share. This brings the total repurchases under its $5 million program to 4,838,000 shares, totaling approximately $1.04 million. CEO Greg Siokas highlighted this as a significant milestone in their capital allocation strategy, reiterating the company's belief that its shares are undervalued.

Cosmos Health Inc. announced an additional repurchase of 133,000 shares of its common stock at an average price of approximately $0.298 per share. This brings the total repurchased shares to approximately 4,488,000 for about $941,000 under its previously announced $5 million share repurchase program. The CEO, Greg Siokas, stated that these repurchases demonstrate confidence in the company's long-term growth prospects and a belief that the shares are undervalued. The program is scheduled to expire on December 31, 2026.

Cosmos Health Inc. announced it has repurchased an additional 215,000 shares of its common stock in the open market at an average price of approximately $0.325 per share. This brings the total shares repurchased under its program to 4,355,000 for approximately $901,000, out of a total authorized program of up to $5 million. The company intends to continue repurchases, with the program expiring on December 31, 2026, reflecting management's belief that shares are undervalued.

Cosmos Health Inc. announced a five-year partnership with Libytec Pharmaceutical S.A. to commercialize its type-2 diabetes medication, DIABIT-IS X (sitagliptin phosphate), in Greece. Cosmos Health will supply the generic alternative to Merck's Januvia®, while Libytec handles distribution and promotion. This agreement is expected to significantly contribute to Cosmos Health's revenue and cash flow, broadening its reach in the European sitagliptin market through Greece's national health insurance system.

Cosmos Health Inc. announced the launch of a subscription-based purchasing model for its proprietary consumer health brands, starting with NOOR Collagen in the United States. Early results are encouraging, showing a repeat purchase rate above 60% and margins exceeding 50%. The company plans to expand this model globally to other products, anticipating benefits such as recurring revenue, enhanced cash-flow visibility, and deeper customer loyalty.